Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.38 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16770231 | 1.00 | ACE (0.55) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL7202874 | 0.91 | ACE (0.43) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL7202871 | 0.91 | ACE (0.43) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL31097756 | 0.88 | ACE (0.51) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30438134 | 0.87 | ACE (0.41) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL4459984 | 0.87 | ACE (0.53) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL4457183 | 0.87 | ACE (0.53) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30804149 | 0.87 | TGFBR1 (0.47) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL4457189 | 0.87 | ACE (0.53) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30437433 | 0.87 | ACE (0.41) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250271447-A1 | MULTIPLEXING HOMOCYSTEINE AND CYSTEINE IN FIRST-TIER SCREENING ASSAYS | US HEALTH (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4511658-A1 | MULTIPLEXING HOMOCYSTEINE AND CYSTEINE IN FIRST-TIER SCREENING ASSAYS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12162924-B2 | Method for the design of fibrillar collagen-mimetic peptide self-assemblies | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2023205248-A1 | MULTIPLEXING HOMOCYSTEINE AND CYSTEINE IN FIRST-TIER SCREENING ASSAYS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20220265791-A1 | TARGET PEPTIDES FOR CANCER THERAPY AND DIAGNOSTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220112269-A1 | METHOD FOR THE DESIGN OF FIBRILLAR COLLAGEN-MIMETIC PEPTIDE SELF-ASSEMBLIES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-04-14 | — | — | US | disclosed |
| US-11008286-B2 | Amino mercaptan compound and preparation method therefor and use thereof in protection against radiation | SHANGHAI KECHOW PHARMA, INC (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20190202779-A1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | SHANGHAI KECHOW PHARMA, INC. (CN) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202779-A1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | MGMT, PRMT8, SULT1A1 | ACE 4638/4885KDM4E 3896/4885MAPT 4790/4885 |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | ACE 3865/4885KDM4E 4525/4885MAPT 4701/4885 |
| US-11008286-B2 | Amino mercaptan compound and preparation method therefor and use thereof in protection against radiation | MGMT, GSTA1, PRMT1 | ACE 2519/4885KDM4E 2423/4885MAPT 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.